Adenoviral vector-based dengue fever vaccine
View Patent ↗The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.
1. A replication-deficient adenoviral vector comprising two or more of the following:
(a) the nucleic acid sequence of SEQ ID NO: 7, which encodes a serotype DV1 Dengue virus pre-membrane and envelope fusion protein,
(b) the nucleic acid sequence of SEQ ID NO: 8, which encodes a serotype DV2 Dengue virus pre-membrane and envelope fusion protein,
(c) the nucleic acid sequence of SEQ ID NO: 9, which encodes a serotype DV3 Dengue virus pre-membrane and envelope fusion protein, or
(d) the nucleic acid sequence of SEQ ID NO: 10, which encodes a serotype DV4 Dengue virus pre-membrane and envelope fusion protein.
2. The adenoviral vector of claim 1 , wherein the adenoviral vector requires complementation of a deficiency in the E1A region, the E1B region, and/or the E4 region of the adenoviral genome for propagation.
3. The adenoviral vector of claim 2 , wherein the adenoviral vector requires complementation of a deficiency in the E1A region and the E1B region of the adenoviral genome for propagation.
4. The adenoviral vector of claim 2 , wherein the adenoviral vector requires complementation of a deficiency in the E1A region, the E1B region, and the E4 region of the adenoviral genome for propagation.
5. The adenoviral vector of claim 4 , wherein the adenoviral genome lacks the entire E1 region and at least a portion of the E4 region.
6. The adenoviral vector of claim 5 , wherein at least one of the nucleic acid sequences is positioned in the deleted E1 region and at least one of the nucleic acid sequences is positioned in the deleted E4 region of the adenoviral genome.
7. The adenoviral vector of claim 1 , which comprises a deficiency in the E3 region of the adenoviral genome.
8. A composition comprising the replication-deficient adenoviral vector of claim 1 , and a pharmaceutically acceptable carrier.
9. A composition comprising two replication-deficient adenoviral vectors and a pharmaceutically acceptable carrier, wherein:
(a) the first adenoviral vector comprises (i) the nucleic acid sequence of SEQ ID NO: 7 and (ii) the nucleic acid sequence of SEQ ID NO: 9, and
(b) the second adenoviral vector comprises (i) the nucleic acid sequence of SEQ ID NO: 8 and (ii) the nucleic acid sequence of SEQ ID NO: 10.
10. A method of inducing an immune response against Dengue virus in a mammal, which comprises administering to the mammal the composition of claim 8 , whereupon each of the nucleic acid sequences encoding a Dengue virus antigen is expressed in the mammal to produce the Dengue virus antigens and wherein the composition is delivered in a sufficient amount to thereby induce an immune response against Dengue virus.
11. The method of claim 10 , wherein the method comprises administering a priming composition to the mammal prior to administering the composition comprising the adenoviral vector to the mammal.
12. The method of claim 10 , wherein the method comprises administering a boosting composition to the mammal after administering the composition comprising the adenoviral vector to the mammal.
13. A method of inducing an immune response against Dengue virus in a mammal, which comprises administering to the mammal the composition of claim 9 , whereupon each of the nucleic acid sequences encoding a Dengue virus antigen is expressed in the mammal to produce the Dengue virus antigens and wherein the composition is delivered in a sufficient amount to thereby induce an immune response against Dengue virus.
14. The adenoviral vector of claim 1 , which comprises the nucleic acid sequence of SEQ ID NO: 7 and the nucleic acid sequence of SEQ ID NO: 9.
15. The adenoviral vector of claim 1 , which comprises the nucleic acid sequence of SEQ ID NO: 8 and the nucleic acid sequence of SEQ ID NO: 10.
16. The adenoviral vector of claim 1 , which comprises the nucleic acid sequence of SEQ ID NO: 7 and the nucleic acid sequence of SEQ ID NO: 8.
17. The adenoviral vector of claim 1 , which comprises the nucleic acid sequence of SEQ ID NO: 7 and the nucleic acid sequence of SEQ ID NO: 10.
18. The adenoviral vector of claim 1 , which comprises the nucleic acid sequence of SEQ ID NO: 8 and the nucleic acid sequence of SEQ ID NO: 9.
19. The adenoviral vector of claim 1 , which comprises the nucleic acid sequence of SEQ ID NO: 9 and the nucleic acid sequence of SEQ ID NO: 10.
20. The adenoviral vector of claim 1 , which comprises (a) the nucleic acid sequence of SEQ ID NO: 7, (b) the nucleic acid sequence of SEQ ID NO: 8, (c) the nucleic acid sequence of SEQ ID NO: 9, and (d) the nucleic acid sequence of SEQ ID NO: 10.